Abstract:G protein coupled receptors (GPCRs) were first characterized as signal transducers that elicit downstream effects through modulation of guanine (G) nucleotide-binding proteins. The pharmacotherapeutic exploitation of this signaling paradigm has created a drug-based field covering nearly 50% of the current pharmacopeia. Since the groundbreaking discoveries of the late 1990s to the present day, it is now clear however that GPCRs can also generate productive signaling cascades through the modulation of β-arrestin functionality. β-Arrestins were first thought to only regulate receptor desensitization and internalization - exemplified by the action of visual arrestin with respect to rhodopsin desensitization. Nearly 20 years ago, it was found that rather than controlling GPCR signal termination, productive β-arrestin dependent GPCR signaling paradigms were highly dependent on multi-protein complex formation and generated long-lasting cellular effects, in contrast to G protein signaling which is transient and functions through soluble second messenger systems. β-Arrestin signaling was then first shown to activate mitogen activated protein kinase signaling in a G protein-independent manner and eventually initiate protein transcription - thus controlling expression patterns of downstream proteins. While the possibility of developing β-arrestin biased or functionally selective ligands is now being investigated, no additional research has been performed on its possible contextual specificity in treating age-related disorders. The ability of β-arrestin-dependent signaling to control complex and multidimensional protein expression patterns makes this therapeutic strategy feasible, as treating complex age-related disorders will likely require therapeutics that can exert network-level efficacy profiles. It is our understanding that therapeutically targeting G protein-independent effectors such as β-arrestin will aid in the development of precision medicines with tailored efficacy profiles for disease/age-specific contextualities.

Lack of beta-arrestin signaling in the absence of active G proteins

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

Phospho-selective Mechanisms of Arrestin Conformations and Functions Revealed by Unnatural Amino Acid Incorporation and 19F-NMR

Genetic Evidence That Β-Arrestins Are Dispensable for the Initiation of Β2-Adrenergic Receptor Signaling to ERK

Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors

Signal transduction at GPCRs: Allosteric activation of the ERK MAPK by β-arrestin

Location-biased β-arrestin conformations direct GPCR signaling

GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation

Relating GPCR domains with functionality: receptor helix-bundle and C-terminus differentially influence GRK-specific functions and β-arrestin-mediated regulation

Manifold Roles of Β-Arrestins in GPCR Signaling Elucidated with Sirna and CRISPR/Cas9.

Receptor-Arrestin Interactions: The GPCR Perspective

β-Arrestin-1 directly interacts with Gαs and regulates its function

Progress studing in the role of arrestins

GPCR Signaling Regulation: The Role of GRKs and Arrestins

Multi-faceted roles of β-arrestins in G protein-coupled receptors endocytosis

Allosteric mechanisms underlie GPCR signaling to SH3-domain proteins through arrestin

β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders

GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the type-1 cannabinoid receptor and the consequences on G protein signalling

GRK2/3/5/6 knockout: The impact of individual GRKs on arrestin-binding and GPCR regulation